October 24, 2021Lipids in Health and Disease51 citationsOpen Access
COVID-19 and lipids. The role of lipid disorders and statin use in the prognosis of patients with SARS-CoV-2 infection
Structured PICO
Does statin therapy improve prognosis and reduce mortality in patients with SARS-CoV-2 infection?
P
Population
Patients with SARS-CoV-2 infection (COVID-19)
I
Intervention
Statin therapy / lipid-lowering treatment
O
Outcome
COVID-19 prognosis and mortality
Statin therapy may improve prognosis and reduce mortality in patients with COVID-19, likely due to their antiviral, anti-inflammatory, immunomodulatory, and cardioprotective properties.
Abstract
The global coronavirus disease 2019 (COVID-19) pandemic caused by the SARS-CoV-2 coronavirus started in March 2020. The conclusions from numerous studies indicate that people with comorbidities, such as arterial hypertension, diabetes, obesity, underlying cardiovascular disease, are particularly vulnerable to the severe course of COVID-19. The available data also suggest that patients with dyslipidemia, the most common risk factor of cardiovascular diseases, are also at greater risk of severe course of COVID-19. On the other hand, it has been shown that COVID-19 infection has an influence on lipid profile leading to dyslipidemia, which might require appropriate treatment. Owing to antiviral, anti-inflammatory, immunomodulatory, and cardioprotective activity, statin therapy has been considered as valuable tool to improve COVID-19 outcomes. Numerous observational studies have shown potential beneficial effects of lipid-lowering treatment on the course of COVID-19 with significant improved prognosis and reduced mortality.